SCHEMBL1433467

SCHEMBL1433467

CC(C)(NC(=O)c1cc2c(NC(=O)c3ccc(N4CCOCC4)cc3)nn(C(=O)OCCCl)c2s1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 7/20 0.49
ABL1 P00519 2/20 0.49
BCR P11274 2/20 0.49
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
BTK Q06187 4/20 0.40
KIT P10721 2/20 0.39
FLT3 P36888 1/20 0.39
CDC7 O00311 1/20 0.38
CHEK1 O14757 1/20 0.38
JAK2 O60674 1/20 0.38
PAK4 O96013 1/20 0.38
NTRK1 P04629 1/20 0.38
PRKCB P05771 1/20 0.38
INSR P06213 1/20 0.38
RET P07949 1/20 0.38
FGFR1 P11362 1/20 0.38
PRKACA P17612 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1433714 0.94 AURKA (0.49) AURKAABL1BCRLMNAMAPT
SCHEMBL1433751 0.94 AURKA (0.49) AURKAABL1BCRLMNAMAPT
SCHEMBL1434171 0.93 AURKA (0.49) AURKAABL1BCRLMNAMAPT
SCHEMBL739466 0.93 AURKA (0.51) AURKAABL1BCRLMNAMAPT
SCHEMBL1433834 0.92 AURKA (0.48) AURKAABL1BCRLMNAMAPT
SCHEMBL1434068 0.92 AURKA (0.48) AURKAABL1BCRLMNAMAPT
SCHEMBL1433459 0.91 AURKA (0.50) AURKAABL1BCRLMNAMAPT
SCHEMBL1434658 0.91 AURKA (0.47) AURKAABL1BCRLMNAMAPT
SCHEMBL1433653 0.91 AURKA (0.47) AURKAABL1BCRLMNAMAPT
SCHEMBL1433899 0.91 AURKA (0.49) AURKAABL1BCRLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809337-B2 Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-08-19 US claimed
US-20130203770-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-08-08 US claimed
US-20110118278-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-19 US claimed
US-8809337-B2 Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-08-19 US disclosed
US-20130203770-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-08-08 US disclosed
US-20110118278-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-19 US disclosed
EP-2300436-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS Nerviano Medical Sciences S.r.l. (IT) 2011-03-30 EP disclosed
WO-2009138440-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203770-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS DMPK, DCK, MAP3K19 AURKA 84/4885ABL1 556/4885BCR 600/4885
US-20110118278-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS DMPK, DCK, MAP3K19 AURKA 84/4885ABL1 556/4885BCR 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.